Eli Lilly
· LLY
886 B
+2.35%
Growth
· FY
Rev. 1Y%
19.56%
RPS 3Y CAGR
11.92%
RPS 10Y CAGR
5.89%
EPS 1Y%
-16.02%
EPS 3Y CAGR
-5.16%
EPS 10Y CAGR
2.99%
Profitability
· FY
Gross Margin
81.44%
Op. Inc. Margin
26.85%
Profit Margin
18.86%
ROE
60.72%
ROA
10.22%
ROCE
23.35%
$0
885.85 B
114.37
5.76
22.76
-250.84
Competitive Advantages
1
Strong Pipeline of Innovative Drugs: A robust pipeline of promising drug candidates in various therapeutic areas.
2
Global Reach and Distribution: Extensive operations in over 125 countries, ensuring broad market access.
Risks
1
Patent Expiration: Loss of exclusivity for key drugs can reduce revenue and profits.
2
Generic Competition: Increasing market share of generic alternatives can erode sales and margins.
Fundamental Charts
Revenue by Geography
Subscribe to unlock chart
Try Premium free for 7 days
Operating Expense Breakdown
Subscribe to unlock chart
Try Premium free for 7 days